Lung cancer multidisciplinary care status and evidence-practice gap: a scoping review protocol Authors: Yunfeng Xu, Zhaofei Liu, Renjian Han, Yuliu Zhang, Ronggui Sun, Junping Wei, Xinhao Fu, Maomao Han, Yue Lu, Xia Hu, Changhe Ouyang, Dong Roman Xu, Kongqi Han, Run Wang Published: 2026 ABSTRACT AbstractIntroductionLung cancer is the leading cause of cancer-related death worldwide, with substantial variations in incidence, stage at diagnosis and outcomes across regions. High-quality, standardised diagnosis and treatment are essential to improving survival and quality of life. Multidisciplinary care (MDC) is a cornerstone of cancer care; however, its implementation faces barriers such as limited resources, uneven policy support and inequitable access to specialised care, particularly in low- and middle-income countries. To date, no global scoping review has systematically mapped lung cancer MDC—covering implementation models, facilitators, barriers, policy frameworks, technology integration and evidence gaps. This review seeks to fill that gap and inform the optimisation of MDC models.Methods and analysisThe Joanna Briggs Institute methodological framework, underpinned by the framework of Arksey and O’Malley and enhanced by Levac and colleagues, will be used for this scoping review. Results will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews (PRISMA-ScR). We will perform a comprehensive search of six electronic databases (PubMed, CINAHL, Scopus, CNKI, VIP and WanFang) and grey literature sources (ClinicalTrials.gov). In addition, we will screen the reference lists of included studies for further relevant publications. Two review authors will independently conduct the screening and data extraction processes; discrepancies will be resolved through consensus or discussion with a third review author. Findings will be presented graphically and tabularly, together with a narrative description.Ethics and disseminationWe will collect all data from published and grey literature, meaning ethical approval is not necessary. To disseminate our findings, we plan to use diverse means, such as publishing in peer-reviewed journals and presenting at academic conferences.Trial registration numberhttps://doi.org/10.17605/OSF.IO/MVSPH. STRENGTH AND LIMITATIONS OF THE STUDY The review will employ a comprehensive methodology aligned with the Joanna Briggs Institute (JBI) methodological framework, underpinned by the framework of Arskey and O’Malley and enhanced by Levac and colleagues. The review will employ a comprehensive methodology aligned with the Joanna Briggs Institute (JBI) methodological framework, underpinned by the framework of Arskey and O’Malley and enhanced by Levac and colleagues. The comprehensive search of the published and grey literature will include systematic reviews and guidelines; using various designs, including quantitative, qualitative and mixed-method studies. The comprehensive search of the published and grey literature will include systematic reviews and guidelines; using various designs, including quantitative, qualitative and mixed-method studies. Two reviewers will independently screen titles/abstracts and full-text articles using Covidence and then extract data using an adapted JBI data extraction template. Two reviewers will independently screen titles/abstracts and full-text articles using Covidence and then extract data using an adapted JBI data extraction template. The adapted JBI data extraction template will be pilot tested by two members of the review team. The adapted JBI data extraction template will be pilot tested by two members of the review team. Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide.1 In 2020, an estimated 19.3 million new cancer cases and nearly 10 million cancer deaths were reported globally.1 Lung cancer accounted for approximately 2.21 million new cases (11.4% of all cancers) and 1.8 million deaths, making it the foremost contributor to cancer mortality.1 Survival outcomes are strongly stage-dependent, with the 5-year survival rate exceeding 70% for patients diagnosed at stage IA but declining to below 10% for those with stage IV disease.2 According to national registry data (2012–2015) in China, the overall 5-year survival rate for patients with lung cancer was only 19.7%.3 The management of lung cancer has become increasingly complex due to rapid advances in diagnostic modalities, staging strategies and therapeutic innovations, alongside the involvement of multiple healthcare providers.4 This complexity underscores the importance of structured and coordinated care models due to the need for timely diagnosis, multimodal treatment planning and ongoing supportive care.4 Multidisciplinary care (MDC) has therefore been established as a benchmark for high-quality oncology services, prioritising patient-centred, team-based approaches to treatment delivery.5 Within the literature, terms such as ‘MDC’, ‘multidisciplinary team (MDT) meetings’ and ‘tumour boards’ are often used interchangeably, although they represent overlapping but distinct components.6 In this review, we define MDC as a longitudinal, integrated model of care spanning the entire disease trajectory, while MDT meetings are defined as an operational mechanism in which specialists convene to discuss individual cases and make evidence-based management decisions.6–8 A typical lung cancer MDC includes professionals from oncology, thoracic surgery, respiratory medicine, radiology, pathology, palliative care, nursing and allied health disciplines.9 This collaborative framework is designed to reduce individual clinician bias, enhance adherence to clinical guidelines and tailor treatment to patient-specific needs.9 Evidence from non-small cell lung cancer (NSCLC) has demonstrated that multidisciplinary input can improve the appropriateness of treatment selection, enhance postoperative recovery, promote guideline-concordant care, expand access to clinical trials and increase psychosocial support.10 11 For example, a retrospective cohort study in the USA reported that the 5-year survival rate was significantly higher among patients with lung cancer managed with an MDC approach compared with conventional care (33.6% vs 23.0%; p<0.001).10 Similarly, a study in Taiwan found that MDT involvement was associated with improved survival outcomes for patients with stage III and IV NSCLC.11 Despite these advantages, MDC implementation remains heterogeneous globally.5 9 In many settings, MDC is limited to episodic MDT meetings rather than extending across the continuum of care. Furthermore, MDC is inherently resource-intensive, demanding significant time, specialised personnel and financial investment.12 These requirements pose particular challenges in resource-limited environments, where workforce shortages, insufficient diagnostic and therapeutic capacity, infrastructural limitations and gaps in policy or professional training often hinder effective delivery.5 Notably, most existing syntheses focus on high-income contexts, leaving an evidence gap regarding adaptable MDC models for low-resource environments. From an implementation science perspective, the Consolidated Framework for Implementation Research (CFIR) provides a lens through which to examine these challenges.13 CFIR integrates constructs related to implementation determinants into five domains: the innovation, outer setting, inner setting, individuals and implementation processes. Its comprehensive structure aligns well with the multi-level challenges of MDC implementation across diverse health systems. Applying this framework enables systematic investigation of who benefits from MDC, who does not and why.13 In this review, CFIR will guide data extraction and analysis to synthesise existing evidence, identify gaps and propose context-appropriate MDC models that are feasible and sustainable, particularly in resource-limited settings. Objectives The aim of this scoping review is to systematically map the global landscape of MDC for lung cancer, identifying implementation models, facilitators, barriers, policy frameworks and integration of innovations to inform the optimisation of MDC models worldwide. Specific objectives of our scoping review are to: (1) describe the existing implementation models of lung cancer MDC across different health systems and settings, (2) identify facilitators and barriers to the effective implementation of lung cancer MDC, (3) examine the extent to which emerging technologies, such as artificial intelligence, are integrated into MDC processes and (4) map existing evidence gaps to guide future research and policy development on lung cancer MDC in resource-limited settings. Methods and analysis To ensure the rigour and clarity of the review process, we will follow the scoping review framework outlined in the Joanna Briggs Institute (JBI) manual for evidence synthesis,14 which is underpinned by the framework of Arskey and O’Malley and enhanced by Levac and colleagues. The protocol was registered with Open Science Framework (https://doi.org/10.17605/OSF.IO/MVSPH). The proposed timeline and current status for the completion of this scoping review are detailed in online supplemental table 3. Inclusion criteria Participants This review will include studies involving adults aged 18 years or older with a confirmed diagnosis of lung cancer, specifically small cell lung cancer (including small cell carcinoma and combined small cell carcinoma) or NSCLC (including adenocarcinoma, squamous cell carcinoma and large cell carcinoma). Studies that explore MDC or MDT processes at any stage of lung cancer management—such as diagnosis, treatment planning, postoperative care, palliation or survivorship—will be eligible, as will studies including patients suspected of lung cancer where MDT meetings are employed. Exclusion criteria comprise studies limited to other thoracic or rare malignancies (eg, lung nodules, mesothelioma, chest wall tumours, carcinoid or mediastinal tumours or cancers metastatic to the lung without primary lung cancer), studies focused solely on risk factors without a confirmed diagnosis and non-English or non-Chinese publications. In addition, studies that only acknowledge the importance of MDC without substantive discussion of its processes, barriers, facilitators or health-related and service-related outcomes will also be excluded. Concepts The study will define MDC as a longitudinal, integrated model of care spanning the entire disease trajectory, while MDT meetings are conceptualised as an operational mechanism in which specialists convene to discuss individual cases and make evidence-based management decisions. Context All settings for the individual with lung cancer will be included. Types of evidence sources Our scoping review will take into account a variety of sources, including any type of empirical research study (eg, quantitative study, qualitative study and mixed-method study), systematic reviews, guidelines, letters to the editor, policy papers and websites. The empirical research study will only be included if it has not been reported in an existing evidence synthesis. Articles published in languages other than English or Chinese will not be considered. Detailed inclusion and exclusion criteria are presented in table 1. Table 1Inclusion and exclusion criterionInclusion criteriaExclusion criteria(1) Adults >age 18.(1) Exclusively the following diagnoses (if none of the inclusion diagnoses on the left are also present): (a) lung nodules; (b) mesothelioma; (c) chest wall tumours; (d) metastatic cancer from other primary sites or (e) rare thoracic malignancies (including carcinoid tumours and mediastinal tumours).(2) One or more of the following diagnoses: (a) lung cancer; (b) small cell lung cancer (including small cell carcinoma/oat cell cancer and combined small cell carcinoma) or (c) non-small cell lung cancer (including adenocarcinoma, squamous cell carcinoma and large cell carcinoma).(2) Studies focusing solely on risk factors (eg, smoking, inactivity, depression) without an established lung cancer diagnosis.(3) Studies that investigate multidisciplinary care (MDC) or multidisciplinary team (MDT) processes across any stage of lung cancer management (eg, diagnosis, treatment planning, surgery, adjuvant therapy, postoperative care, palliation, survivorship).(3) Studies that only mention the importance of MDC/MDT in principle but do not provide substantive discussion of its processes, barriers, facilitators or health/service/implementation-related outcomes.(4) Studies involving individuals suspected of lung cancer (but not yet confirmed), provided that MDT meetings or MDC processes are evaluated.(4) Articles published in languages other than Chinese or English. Inclusion and exclusion criterion Search strategy Six databases will be searched: PubMed, CINAHL, Scopus, CNKI, VIP, WanFang. We will also search clinical trial.gov to locate grey literature. The search will be informed by the search strategies using the key concepts of “Lung cancer” and “MDT”. As per the JBI methodology, an initial search of PubMed will be performed to find potentially relevant keywords and terms for building the final search strategy. The search will then be tailored to each database. The preliminary search strategy for PubMed is included in online supplemental table 1. We will also examine the reference lists of all included research studies for additional resources. Key authors will be contacted with requests to provide relevant full-text papers if these are not available through the library/inter-library loan. All citations will be exported from electronic databases to Endnote to remove duplications.15 After removing duplications, all remaining citations will be imported into Covidence for the subsequent review.16 Source of evidence selection Two researchers will independently review the titles and abstracts to determine whether they meet the review’s inclusion criterion. Full-text versions of potentially relevant publications will be obtained, and two reviewers will independently evaluate them using the study’s inclusion and exclusion criterion. If any disagreements between the reviewers occur, a third reviewer will be consulted to resolve them through discussion. Reasons for full-text paper exclusions will be documented and reported. The Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping reviews (PRISMA-ScR) flow chart with a table of included studies will be used to report the search process (online supplemental table 2).17 The process of searching, screening and selecting studies for the scoping review may discover relevant terms and concepts; the search will then be modified and expanded. Data extraction The adapted JBI data extraction template draft table will be used to systematically capture study characteristics, which will include, but not be limited to: author(s), title, year of publication, population, sample size, methods, key findings. In addition, the template will document determinants and strategies relevant to the five CFIR domains: (1) innovation characteristics (eg, evidence strength of MDC, its adaptability to local contexts, complexity and perceived relative advantage), (2) inner setting (eg, organisational culture, communication networks, resource availability, leadership engagement, compatibility with existing workflows), (3) outer setting (eg, policy mandates, financing mechanisms, partnerships with other institutions, local socioeconomic or regulatory environments), (4) individual (eg, provider self-efficacy, beliefs about MDC, role clarity among team members, individual readiness to change) and (5) implementation process (eg, planning, engagement of stakeholders, audit and feedback loops, adaptation during rollout). To ensure feasibility and relevance, the draft extraction template will first be piloted independently by two reviewers on two to three included studies.18 The preliminary version of the data extraction table is provided in table 2, while the finalised version will be presented in the completed scoping review. Data extraction will be conducted by two independent reviewers, with discrepancies resolved through discussion and, if necessary, consultation with a third reviewer to ensure accuracy and consistency. Table 2Data extraction template formDomainsSpecific informationGeneral information TitleAuthorsCountry and location of conductFull journal nameYear of publication Aim(s) of the study Aim(s) and objective(s) Study characteristics Study designSampling approachSample size and response rate Population studied Demographics: age, biological sex, race/ethnicityGender-related dimensions:Gender identity (eg, woman/man/other)Gender roles (eg, household responsibilities, caregiving responsibilities, occupation, employment status, primary earner status)Gender relations (eg, marital or relationship status, social support, social capital)Institutionalise gender (eg, education level, wage gap, retirement eligibilities, gender inequalities)Clinical: type of lung cancer, treatment received MDC/MDT process and outcomes Description of MDC/MDT processOutcome measures Key findings Effectiveness of MDC/MDTDeterminants—innovation characteristicseg, evidence strength of MDC, its adaptability to local contexts, complexity and perceived relative advantageDeterminants—inner settingeg, organisational culture, communication networks, resource availability, leadership engagement, workflow compatibilityDeterminants—outer settingeg, policy mandates, financing mechanisms, partnerships with other institutions, local socioeconomic or regulatory environmentsDeterminants—individual factorseg, provider self-efficacy, beliefs about MDC, role clarity among team members, individual readiness to changeDeterminants—implementation processeg, planning, engagement of stakeholders, audit and feedback loops, adaptation during rollout MDC, multidisciplinary care; MDT, multidisciplinary team. Data extraction template form Title Title Authors Authors Country and location of conduct Country and location of conduct Full journal name Full journal name Year of publication Year of publication Aim(s) and objective(s) Aim(s) and objective(s) Study design Study design Sampling approach Sampling approach Sample size and response rate Sample size and response rate Demographics: age, biological sex, race/ethnicity Demographics: age, biological sex, race/ethnicity Gender-related dimensions:Gender identity (eg, woman/man/other)Gender roles (eg, household responsibilities, caregiving responsibilities, occupation, employment status, primary earner status)Gender relations (eg, marital or relationship status, social support, social capital)Institutionalise gender (eg, education level, wage gap, retirement eligibilities, gender inequalities) Gender-related dimensions: Gender identity (eg, woman/man/other) Gender identity (eg, woman/man/other) Gender roles (eg, household responsibilities, caregiving responsibilities, occupation, employment status, primary earner status) Gender roles (eg, household responsibilities, caregiving responsibilities, occupation, employment status, primary earner status) Gender relations (eg, marital or relationship status, social support, social capital) Gender relations (eg, marital or relationship status, social support, social capital) Institutionalise gender (eg, education level, wage gap, retirement eligibilities, gender inequalities) Institutionalise gender (eg, education level, wage gap, retirement eligibilities, gender inequalities) Clinical: type of lung cancer, treatment received Clinical: type of lung cancer, treatment received Description of MDC/MDT process Description of MDC/MDT process Outcome measures Outcome measures Effectiveness of MDC/MDT Effectiveness of MDC/MDT Determinants—innovation characteristicseg, evidence strength of MDC, its adaptability to local contexts, complexity and perceived relative advantage Determinants—innovation characteristics eg, evidence strength of MDC, its adaptability to local contexts, complexity and perceived relative advantage Determinants—inner settingeg, organisational culture, communication networks, resource availability, leadership engagement, workflow compatibility Determinants—inner setting eg, organisational culture, communication networks, resource availability, leadership engagement, workflow compatibility Determinants—outer settingeg, policy mandates, financing mechanisms, partnerships with other institutions, local socioeconomic or regulatory environments Determinants—outer setting eg, policy mandates, financing mechanisms, partnerships with other institutions, local socioeconomic or regulatory environments Determinants—individual factorseg, provider self-efficacy, beliefs about MDC, role clarity among team members, individual readiness to change Determinants—individual factors eg, provider self-efficacy, beliefs about MDC, role clarity among team members, individual readiness to change Determinants—implementation processeg, planning, engagement of stakeholders, audit and feedback loops, adaptation during rollout Determinants—implementation process eg, planning, engagement of stakeholders, audit and feedback loops, adaptation during rollout MDC, multidisciplinary care; MDT, multidisciplinary team. Data analysis and presentation Data will be presented graphically and tabularly, as well as a general summary of the number, type and distribution of included studies, together with a narrative description of how they relate to the objectives of the scoping review. Limitations This scoping review will map the breadth and nature of available evidence rather than formally assess the methodological quality or risk of bias of included studies. In addition, heterogeneity in the definitions of MDC/MDT, study designs, healthcare settings and reported outcomes may limit comparability across studies. Although both English and Chinese publications will be included, relevant studies published in other languages may be missed. Patient and public involvement Patients and/or the public were not involved in the design of this scoping review. Ethics and dissemination Ethics approval is not required as the scoping review will synthesise publicly available articles, and participants will not be recruited or consented. The review findings will be disseminated through open access publication and presentation at peer-reviewed academic conferences. Supplementary material